News

Show
news from

Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (1)

Autolus Therapeutics to Present at Conferences During January 2022

Freeline To Participate In Conferences During January 2022

Gyroscope Therapeutics to be acquired for up to $1.5 billion

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

Load more

Search